跳至主要内容
临床试验/EUCTR2015-003953-16-ES
EUCTR2015-003953-16-ES进行中(未招募)1 期

A Phase IIIb study of the efficacy of dexamethasone in irreversible hearing loss prevention in subjects with Ototoxic Oncological Treatment. Otoprotection in cancer treatment.

ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE0 个研究点目标入组 23 人开始时间: 2016年2月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
23

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Men and women ?18 years of age
  • -Patients from oncology department of Complejo Hospitalario Universitario de Albacete who are starting chemotherapy treatment with cisplatin.
  • -Patients without any previous of hearing impairment except age-related pathology.
  • -Patients able to return for all clinic visits andcomplete all study-related procedures
  • -Signed Informed Consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 23
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 23

排除标准

  • ?Retrocochlear hearing loss.
  • ?Meniere's disease
  • ?Autoimmune Inner Ear Disease
  • ?Fluctuating hearing loss
  • ?History of sudden sensory neural hearing loss.
  • ?Previous radiation therapy to the head and neck region.
  • ?Patients with pathology of the middle ear
  • ?Participation in any clinical trial at the same time

研究者

发起方
ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE

相似试验